Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale School of Nursing Digital Theses

School of Nursing

1-1-2017

Identifying Barriers To Implementing Guidelines For Monitoring
Metabolic Syndrome In Patients Prescribed Second-Generation
Antipsychotics In Incarcerated Populations
Carol-Ann Margaret Cenac
carol-ann.cenac@yale.edu

Follow this and additional works at: https://elischolar.library.yale.edu/ysndt

Recommended Citation
Cenac, Carol-Ann Margaret, "Identifying Barriers To Implementing Guidelines For Monitoring Metabolic
Syndrome In Patients Prescribed Second-Generation Antipsychotics In Incarcerated Populations" (2017).
Yale School of Nursing Digital Theses. 1055.
https://elischolar.library.yale.edu/ysndt/1055

This Open Access Thesis is brought to you for free and open access by the School of Nursing at EliScholar – A
Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale School of Nursing Digital
Theses by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more
information, please contact elischolar@yale.edu.

Identifying Barriers to Implementing Guidelines for Monitoring Metabolic Syndrome in Patients
Prescribed Second-generation Antipsychotics in Incarcerated Populations

ii

iii

2
IDENTIFYING BARRIERS TO MONITORING METABOLIC SYNDROME IN
INCARCERATED POPULATIONS

Abstract
Individuals with serious mental illness (SMI) have increased rates of cardiovascular disease
(CVD) and mortality. Also, the evidence indicates that second-generation antipsychotics (SGAs,
a conventional treatment) increase the risk of metabolic syndrome (MetS) often leading to
weight gain, cardiovascular disease (CVD) and type 2 diabetes (DM 2). U. S. correctional
institutions, faced with increased rates of mental illness in its population, are confronted with the
need to assure adequate monitoring for its patients treated with SGAs. This paper reviews
guidelines for monitoring incarcerated patients to ensure early intervention that can improve
clinical outcomes. Characteristics of the incarcerated population and institution-related barriers
to implementing guidelines are identified along with strategies for improved monitoring and
issues for further study.
Keywords
Second generation antipsychotics, metabolic syndrome, mental illness in U. S. jails and prisons,
barriers to care
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Introduction
American incarceration rates are among the highest in the world, and approximately 16 to 20
percent of those incarcerated are diagnosed as seriously mentally ill (SMI) (Aufderheide, 2014,
Treatment Advocacy Center, 2014). Since their introduction in the 1990’s, because of improved
tolerability in comparison to first-generation antipsychotics, second-generation antipsychotics
(SGAs) are the standard treatment for several psychiatric disorders (Morrato, Newcomer, Kamat,
Baser, Harnett, and Cuffel, 2009). However, evidence supports that patients treated with SGAs
have an increased risk of metabolic dysregulation leading to increased vulnerability to type 2
diabetes, dyslipidemia, hypertension, and obesity. A consensus statement from the American
Diabetic Association (Morrato, Newcomer, et al., 2009) recognizes the need to monitor patients
on SGAs for metabolic syndrome (MetS) using recommended monitoring guidelines. Yet, these
guidelines are not routinely followed in the general population (Riordan, Antonini, and Murphy,
2011). Study of adherence to the guidelines in correctional institutions is not available, and it is
unlikely that monitoring in correctional institutions is different than in the community.
Correctional facilities provide treatment to a large mentally ill population, and it is important that
they establish policy and monitor adherence to recommended guidelines.
In a post-deinstitutionalization mental health system, determinants such as inadequate
access to treatment, social isolation, lack of support systems, poverty, and stigma affect the
poorest and sickest psychiatric patients and often lead to homelessness, substance abuse, and
incarceration (Sheth, 2009). These patients face increased rates of morbidity and risk of
mortality because they are disproportionately affected by respiratory illnesses, obesity, diabetes,
substance abuse, sexually transmitted diseases, and cardiovascular disease (Casey, 2005). The
possibility of developing metabolic disorders is amplified when treated with SGAs (Casey, 2005;
American Diabetic Association, 2014; Waterreus, & Laugharne, 2009).
Studies specific to the prevalence and monitoring of MetS in incarcerated populations
prescribed SGAs are lacking. However, given recommended guidelines, best practice guidelines
based on the unique characteristics of incarcerated population can be determined. Laboratory
testing to track metabolic abnormalities cannot be underestimated, and adherence to critical
follow-up is an indispensable step in the clinical management of patients prescribed SGAs. An
examination of this topic must include identification of barriers to adequate care and possible
solutions to address this problem in incarcerated populations.
Purpose
The aim of this paper is to review the current best-evidence guidelines for monitoring for
metabolic syndrome in patients prescribed second-generation antipsychotics. Evidence on
barriers to the implementation of guidelines for monitoring MetS in patients prescribed SGAs in
incarcerated populations will be summarized, including problems with implementation, patient
follow-up and systemic issues.
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Methods
A search was conducted using search terms specific to two areas: Guidelines for monitoring
MetS in patients prescribed SGAs and barriers for implementation of guidelines in incarcerated
populations. Literature was searched from published books, medical, nursing and public health
journals from the period 2000 through 2016, utilizing databases and search engines, including
CINAHL, Cochrane Library, Medline, PubMed, Scopus, and Google Scholar. The reference
lists of specific articles screened were used, as were links suggested when searching articles.
Organizational resources were used specific to each aim and described below. Systematic
reviews and meta-analytic reviews were analyzed using PRISMA Guidelines (Moher, Liberati,
Altman and the PRISMA Group, 2009). Publications written in English language and from the
period 2000 through 2016 were selected for further study.
Guidelines for Monitoring for Metabolic Syndrome in Patients Prescribed SGAs
A search of the literature was conducted using the following search terms: Metabolic syndrome,
dyslipidemia, cardiovascular disease; second-generation antipsychotics; atypical antipsychotics;
clinical management; guidelines for monitoring; laboratory testing; psychiatric or mentally ill
patients. Search terms were combined with AND or OR to specify pertinent results. Resources
of organizations were reviewed including the American Diabetic Association, the American
Heart Association, and National Alliance on Mental Illness. Search results were included if they
focused on current best evidence for metabolic syndrome monitoring in psychiatric patients on
SGAs.
Initially, 164 articles were considered for content suitability, of these, 15 duplicate
articles were removed, 63 were excluded because they focused on metabolic syndrome in the
absence of SGA treatment, or emphasis was on first-generation antipsychotics. Also excluded
were studies based on metabolic syndrome in children and adolescents because this review
involves adult, mostly male, subjects. Eleven articles were excluded based on duplication of
subject content, and same authors on multiple articles with similar content. Finally, 75 articles
were selected for definition of metabolic syndrome, and suggested guidelines and management
of patients on SGAs. Of the 75, 31 presented guidelines for monitoring metabolic syndrome, of
which 6 were included to define and offer criteria for diagnosis of metabolic syndrome. Another
44 focused on the metabolic impact of SGAs, and 11 were included in the review of suggested
guidelines for monitoring.
Barriers to Guideline Implementation in the Incarcerated Population
A search of the literature was conducted using the following search terms: Mental illness;
psychiatric patients; incarceration; jails; prisons; correctional; forensic settings; inmates;
treatment; standards of care; mental health care; barriers to care. Search terms were combined
with AND or OR to specify pertinent results. Organizational resources were reviewed, including
the Agency for Healthcare Research and Quality (AHRQ), The National Commission on
Correctional Healthcare (NCCHC), the Department of Justice, and various U. S. correctional
websites. Search results were included if they focused on the medical and mental health care of
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adult offenders in U. S. jails and prisons. A total of 20 articles were identified that addressed
barriers to care, and 11 were included in review of barriers to implementing guidelines for care
in incarcerated populations. Duplicate articles, articles based in settings outside the U. S., and
articles prior to 2000 were excluded from consideration.
Results
Diagnosing Metabolic Syndrome
The American Heart Association (AHA), International Diabetes Federation (IDF), the World
Health Organization (WHO), the European Group for Study on Insulin Resistance (EGIR), the
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), the
American Association of Clinical Endocrinologists (AACE) and the National Heart, Lung and
Blood Institute (NHLBI) offer definitions of MetS. However, while opinions vary on an exact
diagnosis, one common theme is that MetS is a serious, life-threatening condition that must be
identified and treated.
In recognition of the significance of MetS, a conference to study the “scientific issues
related to the definition of metabolic syndrome” was organized by the National Heart, Lung and
Blood Institute (NHLBI), in collaboration with the American Heart Association (AHA) because
the National Cholesterol Education Program’s Adult Treatment Panel III (ATP III) provided
criteria for metabolic syndrome that varied from that of other organizations (Grundy, Brewer,
Cleeman, Smith, and Lenfant, 2004). For the purpose of this paper, the most commonly used
and clinically relevant definition of MetS, provided by the American Heart Association (AHA),
and the National Heart, Lung and Blood Institute (NHLBI) was used. MetS is a group of risk
factors that increases the risk of abdominal obesity, cardiovascular disease (CVD), and
vulnerability to DM 2 (Grundy, Daniels, Donato, et al., AHA/NHLBI, 2005: 2735-2752).
According to the American Heart Association (AHA), a definitive diagnosis of MetS is made in
the presence of a combination of specific factors; the presence of at least three of the following
risk factors is necessary to meet criteria for a clinical diagnosis of MetS (Grundy, S. M., 2005).
• Fasting glucose ≥ 100mg/dL.
• Low levels of high-density lipoprotein (HDL): Men <40 md/dL; Women <50 mg/dL.
• High levels of triglycerides ≥ 150 mg/mg/dL.
• Central (abdominal) obesity measured by waist circumference: Men: > 40 inches
(102cm); Women: 35 inches (88cm).
• Hypertension (elevated blood pressure): ≥130 millimeters of mercury (mmHg) systolic
blood pressure or ≥85mm Hg diastolic blood pressure (≥ 130/85 mmHg.
Risk of Metabolic Syndrome with Second Generation Antipsychotics (SGAs)
Those diagnosed with a serious mental illness have an increased risk of cardio-metabolic risks
and premature mortality; consistent, on-going monitoring in this group is mandatory (Cohn and
Sernyak, 2006). According to Cohn, & Sernyak (2006), one aim of screening and monitoring is
the early identification of metabolic changes to implement preventative action.
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Each SGA has a specific metabolic risk profile, with Zyprexa and Clozaril deemed to
have the highest metabolic impact (Table 1). However, while some agents are believed to have a
lower glycemic impact, the U. S. Food & Drug Administration (FDA) in 2009, the FDA required
manufacturers of all SGAs to include a black box warning in its packaging about the increased
risk of developing hyperglycemia and diabetes (FDA, 2009; Riordan, Antonini, and Murphy,
2011)). According to Riordan, et al., (2011), in 2004, the FDA also recommended that
manufacturers of SGAs notify providers of the need for glucose testing to monitor patients
started on SGAs, particularly those with a diagnosis of diabetes, at risk for diabetes, or
experiencing symptoms of hyperglycemia.
Metabolic Syndrome in the Seriously Mentally Ill (SMI) Population
Those with mental illness typically have excessive prevalence of morbidity and increased
mortality related to chronic diseases, predominantly substance abuse, obesity, infectious
diseases, diabetes and cardiovascular disease (Casey, 2005; Balf, Stewart, Whitehead & Baker,
2008). Metabolic changes, including hyperglycemia, diabetes, hyperlipidemia and weight gain,
increase the risk of premature morbidity and mortality in SMI patients prescribed SGAs.
The multi-phase Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Project sponsored by the National Institute of Mental Health was conducted to determine the
long-term effects and usefulness of antipsychotic medications in patients with schizophrenia
(Stroup, McEvoy, Swartz, Byerly, Glick, Canive, McGee, Simpson, Stevens, and Lieberman,
2003). The study involved SGAs (olanzapine, quetiapine, risperidone, clozapine, and
ziprasidone) and the first-generation antipsychotics (FGAs) (perphenazine and fluphenazine
decanoate). The data from CATIE and other studies indicate that patients diagnosed with
schizophrenia have higher rates of MetS when compared to the general population and justifies
clinical decisions for regular monitoring (Lieberman et al., 2005; Mitchell, and Dinan, 2010;
Ryan, Collins, and Thakore, 2003).
A retrospective study found infrequent metabolic monitoring of Medicaid patients on
SGAs despite warnings from the Food and Drug Administration (FDA) in 2003 and 2004. The
FDA warned of cases where life-threatening hyperglycemia lead to ketoacidosis, coma, and
death (Morrato, Druss, Hartung, Valuck, Allen, Campagna & Newcomer, 2010). Because of the
metabolic risks associated with SGAs, the ADA together with the American Psychiatric
Association (APA) published a consensus report providing a specific protocol for monitoring
patients on SGAs (ADA/APA, 2004; Morrato, et al., 2010).
To ensure adequate monitoring for MetS, the consensus report from the American
Diabetic Association and American Psychiatric Association (2004) recommends assessments of
personal/family history, weight gain/waist circumference (BMI), blood pressure (BP),
hyperglycemia/DM 2, and lipid profile/hyperlipidemia at baseline, 4 weeks, 8 weeks, 12 weeks,
quarterly, annually and all others at 5 years; more frequent monitoring is recommended if
clinically significant results are identified (Table 3).
Lifestyle Intervention
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Lifestyle assessment involves evaluation of behaviors such as exercise, diet, smoking,
alcohol and substance use. The AHA and other organizations have emphasized the importance of
therapeutic lifestyle changes as first-line therapy in the management of MetS with focus on
obesity and weight reduction. A combination of lifestyle changes and antihypertensive agents are
recommended for patients with MetS who have developed hypertension. Lifestyle changes and
hypoglycemic agents are recommended for those patients who have developed DM 2 to address
keeping hemoglobin A1c levels within target guidelines (Grundy, Brewer, Cleeman, et al.,
2004). According to the ADA/APA (2004) consensus development conference on antipsychotic
drugs, obesity and diabetes, because of associated health risks, ongoing management of patients
prescribed SGAs might require more frequent testing and monitoring where clinically indicated.
Health Care in Correctional Settings
In standards developed by a task force on correctional health services (American Public Health
Association, 2003), policies for managing prisoners with psychiatric diagnoses prescribed
psychotropic medications, must include laboratory monitoring where indicated in accordance
with generally accepted pharmacological principles and contemporary standards in the
community. Ongoing periodic evaluation of medication effectiveness and presence of side
effects must be performed in all cases and be consistent with national community standards of
care (APHA, 2003).
The American Psychiatric Association (APA) has published revised guidelines on
psychiatric services in correctional facilities (2016). A position statement issued by the APA
recommends that SGAs, except Clozapine, be made available, where appropriate, as first-line
treatment throughout the system, including jails, prisons, and youth services facilities. The APA
also advised, “thoughtful management of psychoactive medication in correctional settings” with
concerns for side-effect management.
According to the Group for the Advancement of Psychiatry (APA, 2016) for psychiatric
providers in the criminal justice system, “Treatment within the context of jails and prisons can be
fraught with barriers to quality care, and providers within the system must be committed to
maintaining and providing recognized standards of care and to advocacy for this vulnerable
population” (p. 87). This statement highlights the advocacy role of mental health staff in
correctional settings in the effort to effect change.
Barriers to Care in Correctional Institutions
The literature indicates that a lack of monitoring of patients on SGAs for metabolic dysregulation
can lead to increased morbidity and mortality (Morrato et al., 2010; Nasrallah, et al., 2006). In
spite of evidence-based guidelines for monitoring these patients, and warnings from the FDA in
2003, and 2004, the FDA identified continued infrequent metabolic monitoring of Medicaid
patients (Morrato, et al., 2010). A search for specific studies related to monitoring patients in U.
S. correctional institutions, considered to be the largest provider of mental health services in the
U. S., yielded no results. A literature search, however, yielded data to support inadequate
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delivery of mental health services in most correctional institutions, and given the unique
characteristics of mentally ill incarcerated populations, compliance to guidelines for monitoring
patients prescribed SGAs is important. In any discussion on the delivery of mental health
services in correctional institutions, barriers that influence the gaps in care must be examined.
Barriers identified include, issues of dual loyalty, security, correctional culture, staffing and jobrelated stress, capabilities of the electronic medical records system, social determinants of health,
the stigma of mental health, unclear guidelines and responsibility for monitoring, and low
education levels among inmates (Table 4) .These barriers can influence the standard of care to
correctional patients, including metabolic monitoring for patients prescribed SGAs.
Dual Loyalty.
Qualified health care professionals in correctional institutions are bound by the ethical principles
of their profession in their delivery of patient care. Health care professionals must ensure that
the delivery of care is consistent with professional standards; at no time must care provided to
inmate patients appear to be punitive. The National Commission on Correctional Health Care
(2014) published official standards of care with the goal of improving the quality of care in U. S.
jails “consistent with national clinical guidelines.” However, one of the most significant barriers
faced by health care providers in correctional institutions is the issue of “dual loyalty.” Dual
loyalty refers to the ethical dilemma faced by medical staff providing services in correctional
institutions. There is often “tension” between what is considered ethical medical care versus the
obligations to correctional rules and culture which are not necessarily well aligned (Metzner, and
Fellner, 2010; Pont, Stöver, and Wolff, 2013).
For example, dual loyalty may be an issue when punitive segregation or solitary
confinement is used to punish infractions or control challenging inmates but the adverse effects
of solitary confinement can lead to decompensation in inmates diagnosed with serious mental
illness (Metzner, and Fellner, 2010). Mental health services in segregation units are often
limited to medication and “rounding” by a clinician, and other therapeutic interventions are
usually unavailable for inmates in segregation (Metzner, and Fellner, 2010).
Security issues and correctional culture
Security-restricted inmate movement, punitive segregation (Metzner and Fellner, 2010), and
security related jail/prison lock-downs affect how care is delivered and are barriers specific to the
correctional milieu. Inmate transfer affects providers’ ability to monitor adequately; transfers
before laboratory tests are performed or before intervention can be completed is noteworthy.
Inmates may be transferred between facilities, between jurisdictions, or released to the
community (Edwards, 2005).
Education
Health literacy is required for patients to make informed decisions about care, whether in the
community or incarcerated. Inmate patients need education about the benefits and risks
associated with treatment, the necessity of monitoring for metabolic dysregulation in patients
treated with SGAs, including laboratory testing as an essential monitoring tool. Research has
shown that health literacy skills lead to positive health outcomes, and that inadequate health
literacy is associated with increased mortality (IOM, 2009). According to the IOM, African
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Americans and Hispanics are overrepresented in the lowest levels of literacy proficiency, and
this runs parallel with high school dropout rates; notably, African Americans and Latinos are
disproportionately represented in the correctional population (Wilpner, Woolhandler, et al.,
2009).
Responsibility for monitoring - Psychiatry vs. Medical
The literature suggests that there is confusion on whether medical staff or psychiatric staff must
monitor for MetS in patients on SGAs. Clearly assigned responsibility for monitoring with an
integrated approach to care can help improve health outcomes (Cohn and Sernyak, 2006;
McCulloch, 2013).
Staffing
The profit motive is one factor the might influence staffing in correctional facilities (Daniel,
2007). Inadequate correctional staff can impact safety, inmate movement and the transport of
inmate patients to scheduled monitoring appointments. Inadequate medical staff can affect the
level of care provided to patients. Over booking providers and the effort to see all patients
scheduled for mental health appointments can take precedence over steps like chart review that
can reveal the need for required laboratory monitoring. Professional-role stress, staff burnout,
absenteeism, staff apathy, and negative staff attitudes toward inmate patients are also identified
barriers in the delivery of patient care (Edwards, 2005; Thurston-Snoha, and Mora, 2011;
Lambert, et.al, 2015).
Electronic medical records
The technical capabilities of electronic medical records and programs used in correctional
institutions can become a barrier to care when the system is fragmented and does not integrate
medical, behavioral health and laboratory testing. For example, if systems lack the ability to flag
the charts of patients requiring laboratory testing, routine monitoring requirements may not be
met (Madden, Lakoma, Rusinak, Lu, and Soumeral, 2016).
Social determinants of health
Factors identified by organizations like the WHO are known to affect the health of individuals
and communities. Income and social status, access to education, physical environment, social
supports, genetics, health services and gender affect the lives of individuals. For vulnerable
populations who cycle through the correctional setting, psychosocial factors like insufficient
social supports and low education levels are factors that influence their functioning. Notably,
low education levels are “linked with poor health and more stress” (AHRQ/Zimmerman, Woolf,
and Haley, 2015).
Stigma
The stigma associated with mental health is well documented and can affect staff attitudes
toward the mentally ill inmate, as well as the inmate’s avoidance of being labeled; both can
affect compliance with required tests and monitoring (Lawrence and Kisley, 2010).
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Leadership
There is a legal and ethical basis for providing adequate health care to incarcerated populations.
Necessary health care for prisoners is a significant standard of care proposed by the ABA (2011.
Results of a nationwide survey on the health and health care of U.S. prisoners concluded that
many inmates with “serious chronic physical illnesses fail to receive care while incarcerated”
(Wilper et al, 2009). Inmates face restrictive barriers to care and to ensure that they receive basic
patient-centered care; a strong and committed leadership is needed (NCCHC, 2004).
Discussion
Fontanaros, et al., (2013) identifies that seriously mentally ill inmates are more likely to be
homeless, less likely to have employment, and face more difficulty accessing mental health and
other necessary services in the community than those without mental illness. Statistics suggest
that approximately 50% of incarcerated populations have existing mental health conditions,
addiction issues, as well as chronic diseases like hepatitis C, sexually transmitted diseases,
hypertension, and DM 2 (Rich, Chandler, et al., 2014). The authors also reported “fewer
prisoners receive post-admission medical and diagnostic blood tests.” However, given the
existence of clinically significant comorbidities in this population, monitoring of mentally ill
inmates treated with SGAs is important. Monthly blood pressure monitoring, more frequent and
consistent blood tests, consistent weight monitoring and patient education is proposed for the
management of the inmate population prescribed SGAs. Intervention with agents to address
hyperglycemia/DM 2, hyperlipidemia, and hypertension is suggested, where appropriate.
No literature related to monitoring metabolic syndrome in mentally ill inmates on SGAs
was identified, but based on unique characteristics of incarcerated populations, enough clinical
evidence exists as a basis for determining how best to monitor them. Any recommendation for
the metabolic management of inmates on SGAs must consider the well-documented fact that
patients with serious mental illness are at increased risk for CVD, and DM 2.
The APHA (2003) Standards for Health Services in Correctional Institutions states that
all prisoners have the right to a comprehensive range of psychiatric and mental health services
and should include treatment modalities and services commonly used within mental health
treatment settings in the community. So, why is compliance with monitoring guidelines an issue?
Barriers inherently unique to healthcare and some specific to correctional settings have been
identified, and influence how services are provided to inmates. Some barriers might be
challenging to resolve, however, many can be addressed. Improved patient education, and
improved provider education are solutions to related barriers. A strong administration can
address staffing issues and provide technologic resources that can alleviate associated barriers.
This review recognizes the challenges associated with correctional health care requiring
providers to make a greater effort to monitor, despite these issues and in spite of electronic
limitations; patient monitoring must not be compromised. Chart review and informing receiving
facilities of metabolic-related issues are essential steps that must be completed.
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Implications for Practice
The evidence suggests an improvement in the quality and delivery of patient-centered care where
interdisciplinary collaboration between providers exists (RWJF, 2010; IOM 2001). Given the
complexity of correctional health care, sustainable improvement might depend on a collective
resolve to improve collaboration between providers in the system.
The large population of inmates with psychiatric disorders that are maintained on secondgeneration antipsychotics must be monitored for metabolic changes. It is important that
organizational protocols for monitoring patients adhere to best practice guidelines. If gaps in
monitoring exist, it is important that efforts be made to reduce these deficits (Khatana, Kane,
Taveira, Bauer, & Wu, 2011). Guidelines disseminated by the American Diabetes Association
and other seminal organizations specifically recommend laboratory testing to track metabolic
status.
Lifestyle changes recommended for combating the effects of metabolic change present
unique challenges for incarcerated individuals. In correctional settings, there are inherent
limitations by virtue of being incarcerated. Inmates lack autonomy and have limited control over
dietary choices, opportunities to exercise, as well as conditions conducive to healthy choices
such as adequate sleep. Therefore, in these settings, laboratory testing is a critical tool for
monitoring metabolic status in patients prescribed SGAs.
Correctional facilities must have clear guidelines for monitoring patients on SGAs, with a
well-defined treatment protocol where necessary. Barriers to care must be addressed and a
multidisciplinary approach utilized for the intervention, treatment, and prevention of metabolic
disorders in patients of SGA agents.
Implications for Correctional Health Care
In Estelle v. Gamble, 97 S. Ct. 285 (1976) the court concluded that failure to provide adequate
medical care violates a prisoner’s right to adequate care guaranteed by the Eighth Amendment to
the constitution (Prisoners Rights, 1977). According to Eber (2009), if officials have an
awareness of the risk of “substantial harm” but fail to act, it constitutes a violation of the Eighth
Amendment and may be interpreted as cruel and unusual punishment. Clinical administration
and quality improvement teams must take action on barriers that impede providing care
consistent with national guidelines. Organizations must encourage a culture of collaboration and
effective communication and a willingness to address the issues at hand (O’Daniel, &
Rosenstein, 2008).
Qualified health care professionals in correctional institutions are bound by the ethical
principles of their profession in their delivery of patient care. Health care professionals must
ensure that the delivery of care is consistent with professional standards; at no time must care
provided to inmate patients appear to be punitive. The National Commission on Correctional
Health Care (2014) published official standards of care with the goal of improving the quality of
care in U. S. jails “consistent with national clinical guidelines.” When considered from a
population health perspective, improvement in correctional health care is urgent. The NCCHC
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(2011) postulated that in the correctional setting, the patient “is at the core of professional
practice” and nurses and other professionals must adhere to the ethical principles of respect for
persons, beneficence, nonmaleficence, justice, veracity and fidelity.
Recidivism is a challenge, and for those with serious mentally ill inmates, increased rates
of incarcerations have been noted (Baillargeon, Binswanger, Penn, Williams, and Murray, 2009).
For those with mental illness, more effort is needed by key stakeholders to move this population
to diversion programs such as mental health and drug courts (Daniel, 2007). Efforts to disrupt
recidivism in the mentally ill requires improved discharge planning services in order to connect
inmates to quality mental health services in the community (Baillargeon, Binswanger, Penn,
Williams, & Murray, 2009). Examples include intensive community treatment programs such as
Forensic Assertive Community Treatment (FACT) [pg. 6], meant to improve treatment and
target mentally ill recidivists (Fontanaros et al., 2013), and Assisted Out Treatment (AOT) which
is intended to provide court-ordered, community-based outpatient to SMI individuals
(SAMHSA, 2016).
The risk of death in those with diabetes is 50% higher than those who do not have
diabetes and complications of diabetes can include blindness, renal failure, heart disease, stroke,
and amputation of toes, feet or legs. Approximately 29.1 million people in the U. S. have
diabetes with an approximate cost of $245 billion for medical expenses, lost work, and wages
(CDC, 2014). Therefore, it is vital that systems for integration of laboratory results, medical, and
behavioral health treatment plans be developed to assure that quality and costs are well managed.
Implications for Future Research
Additional research is needed across U. S. correctional institutions on the monitoring of patients
on SGAs, adherence to monitoring guidelines, and protocol for intervention if a metabolic
disturbance is identified. Given the specific needs of inmate populations, a different set of
guidelines might be warranted, but more research is needed in this area. U. S. correctional
institutions have been called de facto mental health institutions because of the high rates of
mentally ill persons in its population; noted for multiple comorbid health conditions,
homelessness and substance use disorders (Casey, 2005; McNeil, Binder, and Robinson, 2005).
Correctional barriers to care, and social determinants such as poor health literacy, inadequate
access to care, and lack of adherence to treatment in the community are among the determinants
that plague this population demanding more aggressive management to improve health
outcomes. Correctional staff must be educated on its obligation to provide basic health care to
this population, including culturally competent patient teaching to address health literacy issues.
Discharge planning services, as previously suggested, must be expanded to enhance access to
mental health services in the community.
Limitations
Guidelines promulgated by the AHA, and other organizations provide criteria for monitoring
patients on SGAs at risk for metabolic syndrome. However, the unique characteristics of
incarcerated populations in U. S. have not been studied, and based on factors previously
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discussed, might require a more rigorous set of rules for management. Access to data on
monitoring protocols in jails, and prisons across the U. S. remain limited and even where
available, records on actual practice are not readily available. The data suggest that even where
protocols exist, adherence might be sporadic, and the lack of transparency in U. S. correctional
institutions limits study and the chance of improving practice.
The lack of published data on monitoring inmates maintained on SGAs for metabolic
changes limits the scope of this review and makes it difficult to issue a definitive conclusion.
More research is required to assess monitoring or the effectiveness of monitoring in various
types of correctional institutions. Correctional institutions across the U. S. are not part of a
uniform system but includes: Federal prisons, state prisons, city jails, county jails, juvenile
detention centers, and privately run prisons. Each system has its rules, regulations, policy and
procedures that interfere with the ability to evaluate issues systematically.
Conclusion
Given the considerable number of mentally ill individuals in correctional populations who are
treated with SGAs, monitoring for MetS is critical. Existing evidence notes inadequate
monitoring, but for this population, monitoring is imperative and providers must reach beyond
silos and other barriers to monitor patients. Identification of comorbid conditions in the mentally
ill, including substance use disorder, increases the risk for cardiovascular disease and diabetes, so
early identification and treatment of metabolic changes or MetS can lead to improved clinical
outcomes; clinical guidelines cannot be disregarded.
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Table 1: SGAs and approximate metabolic impact*
Generic Name
Brand name
Weight gain
Hyperlipidemia
Type 2 diabetes
Clozapine
Clozaril
High
High
High
Olanzapine
Zyprexa
High
High
High
Quetiapine
Seroquel
Moderate
Moderate
Moderate
Risperidone
Risperdal
Moderate
Moderate
Low/Moderate
Iloperidone
Fanapt
Moderate
Low
Low
Asenapine Maleate
Saphris
Low/Moderate
Low
Low
Aripiprazole
Abilify
Low
Low
Low
Lurasidone
Latuda
Low
Low
Low
Ziprasidone
Geodon
Low
Low
Low
Paliperidone
Invega
Low
Low/None
Low
Adapted from: ADA/APA Consensus Development (2004); FDA Safety Information for Patients and
Providers; Church, Hamer, and Ulbrich (2010); Gothefors, Adolfsson, Attvall, et al. (2010). Balf, Stewart,
Whitehead, and Baker, 2008.
*FDA (2005) ordered black box warning for risk of hyperglycemia and diabetes be included in all SGA
packaging
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Table 2: Monitoring for Metabolic Syndrome in Patients on SGA Agents*

Consensus Guidelines* developed with ADA, APA, AACE & NAASO,
2004
Tests/
Baseline
Week 4
Week 8
Week 12
Then, Every Annually
Assessments
3 months
thereafter
Personal/family X
X
History
Weight (BMI) X
X
X
X
X
X
Waist
Circumference
Blood pressure

X

X

X

X

Fasting Blood X
X
X
Glucose
(or
A1C)
Fasting Lipid X
X
X
profile
Lifestyle
X
X
X
Assessment
Source: ADA/APA, 2004. Consensus Development Conference on Antipsychotic Drugs and
Obesity and Diabetes
* More frequent monitoring where clinically indicated
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Table 3: Summary of barriers to care in correctional institutions
Author/Study
Study Design
AHRQ/
Zimmerman,
Woolf, and Haley,
2015.
Community-based
participatory
research study;
IOM, 2009

Barriers Identified

Details

Social Determinants on Health, includes
Education

Low education levels are linked to poor health
and increased stress and affects how individuals
understand, perceive and respond to health
education, including technical medical jargon;
homelessness; low income and social status;
inadequate access to care
Examines the influence of psychosocial factors
and educational disparities and how these issues
are linked to personal health behavior and
outcomes
Unclear guidelines for who is responsible for
patient monitoring that can lead to gaps in
monitoring
The profit motive for private correctional
management organizations may drive inadequate
levels of staffing and can affect the delivery of
services, as can the need to manage costs when
services are managed by a governmental
administration
Access; culture; costs; staffing; security
lockdowns; transfers; Inmate issues: safety, level
of understanding influenced by patients’
understanding - dynamics of jail/prison culture
that interrupts the continuity of patient care,
leading to disparities in patient monitoring
Budgetary constraints; fiscal funding decline and
its overall effect on how services are offered.
Safety issues: mentally ill inmates at risk for
violence are deemed threatening and may not be
escorted to the clinic for follow-up appoints or
monitoring
Stigma of mental illness: The negative perception
of mental illness and its pervasive, damaging
influence across systems including healthcare can
affect staff attitude in how care is provided; some
inmates might seek to avoid being labeled as
having a mental illness
Missing clinical data in electronic health record
system (EHR)
Large EHR might be fragmented or missing
clinical data - might be common in mental health
care and raises concerns about the integrity of
available data
Inadequate leadership; limited resources, and
restrictive correctional barriers are significant
and can be difficult to overcome in jails and
prisons

Insufficient social supports

Cohn and Sernyak,
2006
Review
Daniel, 2007
Editorial

Responsibility: Psychiatrist vs. medical
providers

Edwards, 2005
“In Brief” Article

Correctional culture

Gonzalez, and
Connell, 2014
Peer reviewed
article

Fiscal issues

Lawrence and
Kisley, 2010
Review

Stigma of mental illness

Madden, Lakoma,
Rusinak, Lu, and
Soumeral, 2016
Research and
applications

Limitations of the electronic health
record system (EHR)

National
Commission on
Correctional Health
Care, 2004
Report to Congress
Metzner, & Fellner,

Administration

Profit motive/costs:

Dual loyalty

Dual loyalty: Medical providers in correctional
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2010, Journal
article;
Pont, Stover, and
Wolff, 2013
Peer reviewed
article
Thurston-Snoha,
and Mora, 2011,
Study; Lambert,
Barton-Bellessa,
and Hogan, 2015.

settings face an ethical dilemma between
obligations to inmate care vs. the correctional
system – these are not always well aligned

Professional-role stress

Professional-role stress, burnout, absenteeism,
and even suicide:
Examines the role of job-related stress in
correctional staff and its role in deficient care

